Score Overview
Explore the 2021 public Archive ranking →
Where Ligand Pharmaceuticals Incorporated has ranked, year by year
Showing 5 years ranking history by HDB Score.
Has not reached the top 50 on HDB Score in any year we have ranked.
- LGND
2000: 88.9% · 2021: 48.4% · free through 2021 · longest runs
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-28 | $ 314.10 | — |
1 Year2025-09-26 | $ 169.72 | 85.07% |
5 Years2021-09-28 | $ 86.12 | 264.72% |
10 Years2016-09-28 | $ 63.91 | 391.51% |
20 Years2006-09-28 | $ 25.54 | 12x |
30 Years1996-09-27 | $ 36.19 | 8x |
All Time1992-11-18 | $ 31.39 | 10x |
| Period | Last Price2026-09-28 | 1 Year2025-09-26 | 5 Years2021-09-28 | 10 Years2016-09-28 | 20 Years2006-09-28 | 30 Years1996-09-27 | All Time1992-11-18 |
|---|---|---|---|---|---|---|---|
| Price | $ 314.10 | $ 169.72 | $ 86.12 | $ 63.91 | $ 25.54 | $ 36.19 | $ 31.39 |
| Return | — | 85.07% | 264.72% | 391.51% | 12x | 8x | 10x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 290M | $ 197M | $ 1.35B |
| 2025 | $ 268M | $ 124M | $ 733M |
| 2024 | $ 167M | -$ 4M | $ 256M |
| 2023 | $ 131M | $ 52M | $ 170M |
| 2022 | $ 196M | -$ 33M | $ 211M |
| 2021 | $ 241M | $ 57M | $ 341M |
| 2020 | $ 163M | -$ 2M | $ 411M |
| 2019 | $ 120M | $ 629M | $ 1.06B |
| 2018 | $ 251M | $ 143M | $ 764M |
| 2017 | $ 141M | $ 12M | $ 201M |
| 2016 | $ 108M | -$ 1M | $ 141M |
| 2015 | $ 71M | $ 257M | $ 200M |
| 2014 | $ 64M | $ 12M | $ 167M |
| 2013 | $ 48M | $ 11M | $ 15M |
| 2012 | $ 31M | -$ 527K | $ 12M |
| 2011 | $ 30M | $ 10M | $ 17M |
| 2010 | $ 23M | -$ 12M | $ 22M |
| 2009 | $ 38M | -$ 1M | $ 53M |
| 2008 | $ 27M | -$ 98M | $ 80M |
| 2007 | $ 12M | $ 281M | $ 94M |
| 2006 | $ 140M | -$ 31M | $ 171M |
| 2005 | $ 176M | -$ 36M | $ 86M |
| 2004 | $ 163M | -$ 45M | |
| 2003 | $ 141M | -$ 37M | $ 99M |
| 2002 | $ 96M | -$ 32M | $ 64M |
| 2001 | $ 76M | -$ 42M | $ 37M |
| 2000 | $ 48M | -$ 72M | $ 23M |
| 1999 | $ 40M | -$ 74M | $ 47M |
| 1998 | $ 17M | -$ 117M | $ 32M |
| 1997 | $ 51M | -$ 100M | $ 62M |
| 1996 | $ 36M | -$ 37M | $ 34M |
| 1995 | $ 24M | -$ 64M | $ 16M |
| 1994 | $ 13M | -$ 27M | $ 7M |
Ligand Pharmaceuticals Incorporated fundamental performance
Between 2020 and 2025, revenue grew from $ 163M to $ 268M and net income went from -$ 2M to $ 124M. Revenue increased in 3 of those 5 years; net income in 3.
Between 2015 and 2025, revenue grew from $ 71M to $ 268M and net income declined from $ 257M to $ 124M. Revenue increased in 7 of those 10 years; net income in 7.
Ligand Pharmaceuticals Incorporated currently holds a 20-year HDB Score of 5.5 out of 10. How the HDB Score is calculated.
Membership
Continue LGND’s history
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,816 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
